Skip to main content

Advertisement

SpringerLink
Log in

Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)

  • Original Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Purpose

Inflammation and Cyclooxygenase-2 (COX-2) as a part of it are common in BPH specimens and may play a role in the pathogenesis of the disease through cytokines that promote cell growth or lead to smooth muscle contraction. The aim of this study is to analyze whether combination therapy with omega-3 fatty acids, which have anti-inflammatory and COX-2 inhibitory effects, and tamsulocin plus finasteride offers an advantage compared to tamsulocin plus finasteride therapy in patients with BPH.

Materials and methods

This is a single-center blinded clinical trial. One hundred consecutive men between 50 and 70 years of age and no other comorbidities with LUTS and BPH were entered into the study and were randomized to receive omega-3 fatty acids 300 mg three times a day with meals plus tamsulocin 0.4 mg at bed time and finasteride 5 mg/day (study group) versus tamsulocin 0.4 mg at bed time and finasteride 5 mg/day (control group) for 6 months. The efficacy and safety of treatments were assessed at baseline and at month one, three and six.

Results

In our population, both treatments (groups study and control) produced statistically significant improvements in IPSS, Q max, Q ave and prostate volume from baseline during follow-up (p < 0.05). We found that study group showed higher improvement in IPSS (p = 0.007), Q max (p = 0.011) and Q ave (p = 0.004) at the 1 month interval. These higher improvements last at month three and six (p < 0.05). Prostate volume in the study group also showed more improvement at month six (p = 0.000). Adverse effects were the same in both groups during the study.

Conclusion

It can be concluded that association of omega-3 fatty acids with tamsulocin and finasteride may produce better clinical results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (2010) An overview on 5α -reductase inhibitors. Steroids 75:109–153

    Article  CAS  PubMed  Google Scholar 

  • Calder PC (2010) Omega-3 fatty acids and inflammatory processes. Nutrients 2:355–374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carraro JC, Raynaud JP, Kock G, Chisolm GD, Di Silverio F, Teillac P (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of BPH: a randomized international study of 1098 patients. Prostate 29:231–240

    Article  PubMed  Google Scholar 

  • Chughtai B, Lee R, Te A, Kaplan S (2011) Role of Inflammation in benign prostatic hyperplasia. Rev Urol 13(3):147–150

    PubMed  PubMed Central  Google Scholar 

  • De Marzo AM, Marchi VL, Epstein JI (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am Pathol 155:1985–1992

    Article  Google Scholar 

  • Di Silverio F, Gentile V, De Matteis A, Voria G, Sciarra A (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43(2):164–175

    Article  PubMed  Google Scholar 

  • Di Silverioa F, Bosmanb C, Salvatoric M, Albanesia L, Pannunzic LP, Ciccarielloa M, Cardia A, Salvatoria G, Sciarraa A (2005) Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract (LUTS) and benign prostatic hyperplasia (BPH) symptoms. Eur Urol 47:72–79

    Article  Google Scholar 

  • Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N (2001) Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 46(1):45–51

    Article  CAS  PubMed  Google Scholar 

  • Hla T, Bishop D, Liu CH, Schaefers HJ, Trifan OC (1999) Cyclooxygenase 1 and 2 isoenzymes. Int J Biochem Cell Biol 31:551–557

    Article  CAS  PubMed  Google Scholar 

  • Hussain T, Gupta S, Mukhtar H (2003) Cyclooxygenase 2 and prostate carcinogenesis. Cancer Lett 191:125–135

    Article  CAS  PubMed  Google Scholar 

  • Irani J (2006) Are all alpha-blockers created the same? Eur Urol 49:420–422

    Article  PubMed  Google Scholar 

  • Maroon JC, Bost JW (2006) Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg Neurol 65(4):326–331

    Article  PubMed  Google Scholar 

  • McNicholas TA, Kirby RS (2012) Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ (eds) Campbell walsh urology, 10th edn. Elsevier Saunders, Philadelphia, pp 2611–2655

    Chapter  Google Scholar 

  • McVary KT (2007) A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 29:387–398

    Article  CAS  PubMed  Google Scholar 

  • Montorsi F, Moncada I (2006) Safety and tolerability of treatment for BPH. Eur Urol Suppl 5:1004–1012

    Article  CAS  Google Scholar 

  • Nickel JC (2008) Inflammation and benign prostatic hyperplasia. Urol Clin North Am 35(1):109–115

    Article  PubMed  PubMed Central  Google Scholar 

  • Nickel JC, Downey J, Young I (1999) Asymptomatic inflammation and/or infection in BPH. BJU Int 84:976–981

    Article  CAS  PubMed  Google Scholar 

  • O’Neill GP, Ford AW (1993) Expression of mRNA for cyclooxygenase 1 and 2 in human tissues. FEBS Lett 330:156–160

    PubMed  Google Scholar 

  • Robert G, Salagierski M, Schalken JA, de La Taille A (2010) Inflammation and benign prostatic hyperplasia: cause or consequence? [in French]. Prog Urol 20(6):402–407

    Article  CAS  PubMed  Google Scholar 

  • Roehrborn CG (2012) Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ (eds) Campbell walsh urology, 10th edn. Elsevier Saunders, Philadelphia, pp 2570–2611

    Chapter  Google Scholar 

  • Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I et al (2010) The effects of combination therapy with dutasteride and tamsulocin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131

    Article  CAS  PubMed  Google Scholar 

  • Shrivastava A, Gupta VB (2012) Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health 3(1):10–19

    PubMed  PubMed Central  Google Scholar 

  • Tindall DJ, Rittmaster RS (2008) The rationale for inhibiting 5α-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 179(4):1235–1242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tsuji S, Tsujii M, Kawano S, Hori M (2001) Cyclooxygenase 2 upregulation as a perigenetic change in carcinogenesis. J ExpClin Cancer Res 20:117–129

    CAS  Google Scholar 

  • Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpression prostaglandin endoperoxide synthase 2. Cell 83:493–501

    Article  CAS  PubMed  Google Scholar 

  • Wang W, Bergh A, Damber JE (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 61(1):60–72

    Article  CAS  PubMed  Google Scholar 

  • Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM et al (2001) Cyclooxygenase 2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61:8617–8623

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

    Alireza Ghadian & Mehran Rezaei

Authors
  1. Alireza Ghadian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehran Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehran Rezaei.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghadian, A., Rezaei, M. Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Inflammopharmacol 25, 451–458 (2017). https://doi.org/10.1007/s10787-017-0343-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-017-0343-2

Keywords

Search

Navigation